Trial · NCT04639843
Doxorubicin, CC-(486) (5-azacitidine), Romidepsin, and Duvelisib (hARD) for T-cell Lymphoma
NCT04639843, Phase 1, Withdrawn, National Cancer Institute (NCI)
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Doxorubicin, CC-(486) (5-azacitidine), Romidepsin, and Duvelisib (hARD) for T-cell Lymphoma. Trials, record NCT04639843. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04639843
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Doxorubicin, CC-(486) (5-azacitidine), Romidepsin, and Duvelisib (hARD) for T-cell Lymphoma
- NCT number
- NCT04639843
- Status
- Withdrawn
- Phases
- Phase 1
- Enrollment
- 0 participants, actual
- Lead sponsor
- National Cancer Institute (NCI)
- Conditions
Adult T-cell Leukemia/Lymphoma, Extranodal NK-/T-cell Lymphoma, Nasal Type, Enteropathy-Associated T-Cell Lymphoma, Monomorphic Epiteliotrophic Intestinal T-cell Lymphoma, Hepatosplenic T-cell Lymphoma
- Interventions
- CC-486 (5-azacitidine), Duvelisib, Romidepsin, Doxorubicin
- First posted
- 2020-11-23
- Last updated
- 2022-11-04
Source ClinicalTrials.gov
Registered outcomes8
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Safety and tolerability | 8 cycles | Rate and severity of AEs will be summarized by grade and type of toxicity |
| Primary | Maximum tolerated dose (MTD) | 21 days | Frequency (number and percentage) of treatment emergent adverse events |
| Secondary | Progression-free survival | every 2 months for 6 months, every 3 months for 2 years, every 6 months for 2 years, then annually | The response rate will be determined and reported along with a 95% confidence interval |
| Secondary | Overall Repsonse Rate | 8 cycles | The response rate will be determined and reported along with a 95% confidence interval |
| Secondary | Complete Response Rate | 8 cycles | The response rate will be determined and reported along with a 95% confidence interval |
| Secondary | Duration of response (DOR) | every 2 months for 6 months, every 3 months for 2 years, every 6 months for 2 years, then annually | The response rate will be determined and reported along with a 95% confidence interval |
| Secondary | Overall Survival (OS) | every 2 months for 6 months, every 3 months for 2 years, every 6 months for 2 years, then annually | The response rate will be determined and reported along with a 95% confidence interval |
| Secondary | Event Free Survival (EFS) | every 2 months for 6 months, every 3 months for 2 years, every 6 months for 2 years, then annually | The response rate will be determined and reported along with a 95% confidence interval |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT04639843
GET https://conductscience.org/api/trials/v1/NCT04639843/registered